Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433540 | 1.00 | HPGD (0.67) | HPGDALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL14030871 | 0.82 | CRHBP (0.51) | HPGDALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL13416408 | 0.82 | KDM1A (0.68) | HPGDALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL11900441 | 0.81 | ALDH1A1 (0.70) | HPGDALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL14030915 | 0.81 | MAPT (0.50) | HPGDALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL4361189 | 0.81 | KDM1A (0.62) | HPGDALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL7734705 | 0.80 | MAPK1 (0.74) | HPGDALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL554401 | 0.80 | CA1 (0.54) | HPGDALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL29354065 | 0.80 | CA1 (0.54) | HPGDALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL15437984 | 0.80 | KMT2A (0.77) | HPGDALDH1A1LMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608394-B2 | Nanoparticles and formulations for printing | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-21 | — | — | US | claimed |
| EP-4703470-A1 | CELLULASE VARIANTS | AB Enzymes Finland Oy (FI) | 2026-03-04 | — | — | EP | disclosed |
| US-12545720-B2 | Anti-alpha-synuclein antibodies | UCB Biopharma SRL (BE) | 2026-02-10 | — | — | US | disclosed |
| US-12410244-B2 | Anti-alpha-synuclein antibodies | UCB Biopharma SRL (BE) | 2025-09-09 | — | — | US | disclosed |
| US-20250277211-A1 | LPA inhibitors and uses thereof | KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| EP-4567112-A1 | RNA INHIBITOR FOR INHIBITING APOC3 GENE EXPRESSION AND USE THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| CN-113862268-B | AGT inhibitors and uses thereof | 厦门甘宝利生物医药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250066789-A1 | AGT Inhibitor and Use Thereof | KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4491727-A1 | LPA INHIBITOR AND USE THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-111655727-B | Anti-alpha synuclein antibodies | UCB生物制药有限责任公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-113497633-B | Method for improving IP2 index of zero intermediate frequency and low intermediate frequency architecture receiver and architecture thereof | 海能达通信股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023066236-A1 | AGT INHIBITOR AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-11608394-B2 | Nanoparticles and formulations for printing | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-21 | — | — | US | disclosed |
| US-20220340648-A1 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES | UCB Biopharma SRL (BE) | 2022-10-27 | — | — | US | disclosed |
| US-11478501-B2 | Compositions and methods for inhibiting HMGB1 expression | DICERNA PHARMACEUTICALS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11446383-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20220220192-A1 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES | UCB Biopharma SRL (BE) | 2022-07-14 | — | — | US | disclosed |
| CN-114703184-A | LPA inhibitor and use thereof | 厦门甘宝利生物医药有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114351274-A | High-light-fastness polyvinyl chloride composite material for textilene mesh cloth and preparation process of textilene mesh cloth | 台州东海塑料品制造有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11292831-B2 | Anti-alpha synuclein antibodies | UCB Biopharma SRL (BE) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340648-A1 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES | SNCA, PARK7, SYNJ1 | HPGD 4427/4885ALDH1A1 3176/4885LMNA 2421/4885 |
| US-12410244-B2 | Anti-alpha-synuclein antibodies | SNCA, PARK7, SYNJ1 | HPGD 4427/4885ALDH1A1 3176/4885LMNA 2421/4885 |
| US-11446383-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | HPGD 3969/4885ALDH1A1 1878/4885LMNA 793/4885 |
| US-20220220192-A1 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES | SNCA, PARK7, SYNJ1 | HPGD 4445/4885ALDH1A1 3160/4885LMNA 2475/4885 |
| US-11478501-B2 | Compositions and methods for inhibiting HMGB1 expression | HMGB1, HMGB3, HMGB2 | HPGD 1460/4885ALDH1A1 3787/4885LMNA 480/4885 |
| US-12545720-B2 | Anti-alpha-synuclein antibodies | SNCA, PARK7, CDR2 | HPGD 4348/4885ALDH1A1 3372/4885LMNA 1795/4885 |
| US-11292831-B2 | Anti-alpha synuclein antibodies | SNCA, PARK7, SYNJ1 | HPGD 4498/4885ALDH1A1 3587/4885LMNA 2550/4885 |
| US-20250066789-A1 | AGT Inhibitor and Use Thereof | AGT, AGTR1, AGTR2 | HPGD 2694/4885ALDH1A1 2543/4885LMNA 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.